Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PainChek Ltd ( (AU:PCK) ) just unveiled an announcement.
PainChek Ltd has secured its first US customer, Jewish Home Family, following its recent FDA De Novo clearance for its pain assessment app, marking its entry into the US market. This agreement, which includes a three-year term and upfront payment, positions PainChek to capitalize on a $100 million annual market opportunity in the US aged care sector. The company is accelerating its market penetration through strategic partnerships and participation in major industry conferences, aiming to expand its presence in the North American long-term care market.
More about PainChek Ltd
PainChek Ltd is a company that develops AI-powered pain assessment and monitoring applications. Their primary product is a facial recognition and behavioral analysis tool designed to assess pain in individuals unable to self-report, providing real-time, objective data to caregivers. The company is focused on the aged care market, with a significant emphasis on the US market following recent regulatory clearance.
Average Trading Volume: 4,048,709
Technical Sentiment Signal: Buy
Current Market Cap: A$134.6M
Find detailed analytics on PCK stock on TipRanks’ Stock Analysis page.